Impurities test for Amoxicillin (EP-8.0 method)

Significance of the topic

Reliable impurity profiling of amoxicillin is essential to ensure pharmaceutical quality, patient safety and regulatory compliance.

Study Objectives and Overview

This study evaluates the European Pharmacopoeia 8.0 HPLC method for detecting and quantifying major impurities in amoxicillin samples. It compares test solutions with reference standards to confirm method suitability and impurity separation efficiency.

Methodology

• Sample preparation: two test solutions containing metronidazole and reference mixtures with cefadroxil and amoxicillin.
• Chromatographic conditions: gradient elution using mobile phases A (acetonitrile and phosphate buffer, pH 5.0) and B (higher acetonitrile content), flow rate 1.0 mL/min, column temperature 25 °C, injection volume 50 µL.
• Detection: UV at 254 nm, run time 65 minutes.

Used Instrumentation

• HPLC system: UltiMate 3000 LC
• Column: Hypersil Gold, 4.6 × 250 mm, 5 µm
• Detector: UV lamp at 254 nm

Main Results and Discussion

Resolution between amoxicillin and cefadroxil peaks exceeded the USP criterion (NLT 2.0) with an observed value of 10.01. Relative retention times for impurities C and J fell within specified limits, confirming clear separation and reliable identification.

Benefits and Practical Applications

This validated HPLC method offers high specificity and reproducibility for routine QC of amoxicillin products. It enables accurate impurity monitoring critical for batch release and stability studies.

Future Trends and Potential Applications

Advances may include coupling with mass spectrometry for enhanced detection, adopting green solvent strategies to reduce environmental impact, and integrating automated data analysis to streamline workflows.

Conclusion

The European Pharmacopoeia method delivers robust performance for amoxicillin impurity analysis. Its clear separation, sensitivity and compliance with regulatory standards make it a reliable tool for pharmaceutical quality control.